Skip to main content

Table 1 Overview of included study measures and scales in the TRACK-PD study

From: The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson’s disease

Method Outcome Scales Visit 1 (Baseline) Visit 2 (2 Years)˟ Visit 3 (4 Years)˟
Assessed by trial assessor Motor functioning in ‘ON’ state MDS-UPDRS III (including H&Y stage) X* X* X*
MDS-UPDRS IV X* X* X*
Neuropsychological symptoms MoCA X X X
Phonemic and semantic fluency X X X
15 Words Test X X X
Benton Judgment of Line Orientation X X X
Letter Number Sequencing X X X
Symbol Digit Modalities Test X X X
MDS-UPDRS I X* X* X*
Demographics and lifestyle Medical history X X X
Medication X X X
Biospecimen EDTA Plasma (DNA) X   
Pax Gene (RNA) X   
Brain structure and function Resting-state functional MRI X X X
Structural MRI (T1, T2*, neuromelanin, DWI) X X X
Wearable sensors Motor parameters IMU including 3-axis accelerometer and 3-axis gyroscope X X X
Self-reported patient questionnaires Neuropsychiatric symptoms BDI X X X
QUIP-RS X X X
PAS X X X
Quality of life PDQ-8 X* X* X*
Autonomic symptoms SCOPA-AUT X X X
Sleep disorders RBDQ X X X
Various MDS-UPDRS II X* X* X*
  1. BDI Beck Depression Inventory, HC healthy controls, H&Y Hoehn and Yahr scale, IMU Inertial Measurement Unit, MDS-UPDRS Movement Disorders Society Unified Parkinson Disease Rating Scale, MoCA Montreal Cognitive Assessment, NPA Neuropsychological assessment, PAS Parkinson Anxiety Scale, PD Parkinson’s disease patients, PDQ-8 Parkinson’s Disease Questionnaire, QUIP-RS Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease, RBDSQ REM-sleep behaviour disorder screening questionnaire, SCOPA-AUT Scales for Outcomes in Parkinson’s Disease - Autonomic dysfunction questionnaire
  2. ˟ ± 60 days; * Only for PD patients